Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Toward Progress in Quantitative Translational Medicine: A Call to Action.

Venkatakrishnan K, Zheng S, Musante CJ, Jin JY, Riggs MM, Krishnaswami S, Visser SAG.

Clin Pharmacol Ther. 2019 Nov 21. doi: 10.1002/cpt.1687. [Epub ahead of print]

PMID:
31750932
2.

Anti-inflammatory properties of fermented pine (Pinus morrisonicola Hay.) needle on lipopolysaccharide-induced inflammation in RAW 264.7 macrophage cells.

Chiu HF, Wang HM, Shen YC, Venkatakrishnan K, Wang CK.

J Food Biochem. 2019 Nov;43(11):e12994. doi: 10.1111/jfbc.12994. Epub 2019 Jul 28.

PMID:
31659812
3.

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.

Faessel HM, Mould DR, Zhou X, Faller DV, Sedarati F, Venkatakrishnan K.

Br J Clin Pharmacol. 2019 Nov;85(11):2568-2579. doi: 10.1111/bcp.14078. Epub 2019 Sep 4.

4.

Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling.

Bottino DC, Patel M, Kadakia E, Zhou J, Patel C, Neuwirth R, Iartchouk N, Brake R, Venkatakrishnan K, Chakravarty A.

Clin Cancer Res. 2019 Nov 15;25(22):6633-6643. doi: 10.1158/1078-0432.CCR-18-3882. Epub 2019 Jul 18.

PMID:
31320596
5.

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.

Tugnait M, Gupta N, Hanley MJ, Sonnichsen D, Kerstein D, Dorer DJ, Venkatakrishnan K, Narasimhan N.

Clin Pharmacol Drug Dev. 2019 Jul 9. doi: 10.1002/cpdd.723. [Epub ahead of print]

PMID:
31287236
6.

Effect of a balanced nutrition meal replacement diet with altered macromolecular composition along with caloric restriction on body weight control.

Lu TM, Chiu HF, Chen YM, Shen YC, Han YC, Venkatakrishnan K, Wang CK.

Food Funct. 2019 Jun 19;10(6):3581-3588. doi: 10.1039/c9fo00192a.

PMID:
31161182
7.

Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.

Suri A, Mould DR, Song G, Collins GP, Endres CJ, Gomez-Navarro J, Venkatakrishnan K.

Clin Pharmacol Ther. 2019 Dec;106(6):1268-1279. doi: 10.1002/cpt.1530. Epub 2019 Jul 9.

PMID:
31152605
8.

Extensive review of popular functional foods and nutraceuticals against obesity and its related complications with a special focus on randomized clinical trials.

Venkatakrishnan K, Chiu HF, Wang CK.

Food Funct. 2019 May 22;10(5):2313-2329. doi: 10.1039/c9fo00293f. Review.

PMID:
31041963
9.

Come Dance With Me: Transformative Changes in the Science and Practice of Drug-Drug Interactions.

Venkatakrishnan K, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2019 Jun;105(6):1272-1278. doi: 10.1002/cpt.1433. Epub 2019 Apr 20.

PMID:
31004453
10.

Model-Based Meta-Analysis: Optimizing Research, Development, and Utilization of Therapeutics Using the Totality of Evidence.

Upreti VV, Venkatakrishnan K.

Clin Pharmacol Ther. 2019 Nov;106(5):981-992. doi: 10.1002/cpt.1462. Epub 2019 Jun 14. Review.

PMID:
30993679
11.

Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.

Zhou X, Lockhart AC, Fu S, Nemunaitis J, Sarantopoulos J, Muehler A, Rangachari L, Bargfrede M, Venkatakrishnan K.

J Clin Pharmacol. 2019 Sep;59(9):1204-1215. doi: 10.1002/jcph.1416. Epub 2019 Apr 15.

PMID:
30985952
12.

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.

Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD.

Br J Clin Pharmacol. 2019 Jul;85(7):1464-1473. doi: 10.1111/bcp.13915. Epub 2019 May 17.

13.

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators.

J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.

PMID:
30707661
14.

Down-regulation of partial substitution for staple food by oat noodles on blood lipid levels: A randomized, double-blind, clinical trial.

Liao MY, Shen YC, Chiu HF, Ten SM, Lu YY, Han YC, Venkatakrishnan K, Yang SF, Wang CK.

J Food Drug Anal. 2019 Jan;27(1):93-100. doi: 10.1016/j.jfda.2018.04.001. Epub 2018 May 26.

15.

The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.

Tugnait M, Gupta N, Hanley MJ, Venkatakrishnan K, Sonnichsen D, Kerstein D, Dorer DJ, Narasimhan N.

Clin Pharmacol Drug Dev. 2019 Aug;8(6):734-741. doi: 10.1002/cpdd.641. Epub 2018 Dec 20.

16.

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors.

Zhou X, Pusalkar S, Chowdhury SK, Searle S, Li Y, Ullmann CD, Venkatakrishnan K.

Invest New Drugs. 2019 Aug;37(4):666-673. doi: 10.1007/s10637-018-0693-7. Epub 2018 Nov 6.

PMID:
30397836
17.

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ.

JAMA Oncol. 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10.

18.

Selective drug-free cancer apoptosis by three-dimensional self-targeting magnetic nickel oxide nanomatrix.

Vijayakumar SC, Venkatakrishnan K, Tan B.

Nanomedicine (Lond). 2018 Oct;13(19):2469-2490. doi: 10.2217/nnm-2018-0008. Epub 2018 Oct 17.

PMID:
30328379
19.

SERS-Active 3D Interconnected Nanocarbon Web toward Nonplasmonic in Vitro Sensing of HeLa Cells and Fibroblasts.

Chowdhury AKMRH, Tan B, Venkatakrishnan K.

ACS Appl Mater Interfaces. 2018 Oct 24;10(42):35715-35733. doi: 10.1021/acsami.8b10308. Epub 2018 Oct 9.

PMID:
30264558
20.

Label-Free SERS Quantum Semiconductor Probe for Molecular-Level and in Vitro Cellular Detection: A Noble-Metal-Free Methodology.

Keshavarz M, Tan B, Venkatakrishnan K.

ACS Appl Mater Interfaces. 2018 Oct 17;10(41):34886-34904. doi: 10.1021/acsami.8b10590. Epub 2018 Oct 3.

PMID:
30239189
21.

Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy.

Patel CG, Rangachari L, Patti M, Griffin C, Shou Y, Venkatakrishnan K.

Clin Pharmacol Drug Dev. 2019 Jul;8(5):637-646. doi: 10.1002/cpdd.613. Epub 2018 Aug 31.

PMID:
30168905
22.

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces.

Pusalkar S, Plesescu M, Gupta N, Hanley M, Venkatakrishnan K, Wu JT, Xia C, Zhang X, Chowdhury S.

Cancer Chemother Pharmacol. 2018 Nov;82(5):803-814. doi: 10.1007/s00280-018-3671-z. Epub 2018 Aug 20.

PMID:
30128949
23.

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.

Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K.

Clin Pharmacokinet. 2019 Apr;58(4):431-449. doi: 10.1007/s40262-018-0702-1. Review.

24.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D.

Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6.

PMID:
30082475
25.

Non plasmonic semiconductor quantum SERS probe as a pathway for in vitro cancer detection.

Haldavnekar R, Venkatakrishnan K, Tan B.

Nat Commun. 2018 Aug 3;9(1):3065. doi: 10.1038/s41467-018-05237-x.

26.

Multiplex Photoluminescent Silicon Nanoprobe for Diagnostic Bioimaging and Intracellular Analysis.

Keshavarz M, Tan B, Venkatakrishnan K.

Adv Sci (Weinh). 2017 Dec 31;5(3):1700548. doi: 10.1002/advs.201700548. eCollection 2018 Mar.

27.

Beneficial effect of Burdock complex on asymptomatic Helicobacter pylori-infected subjects: A randomized, double-blind placebo-controlled clinical trial.

Yen CH, Chiu HF, Huang SY, Lu YY, Han YC, Shen YC, Venkatakrishnan K, Wang CK.

Helicobacter. 2018 Jun;23(3):e12469. doi: 10.1111/hel.12469. Epub 2018 Mar 8.

PMID:
29520881
28.

Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.

Gupta N, Hanley MJ, Diderichsen PM, Yang H, Ke A, Teng Z, Labotka R, Berg D, Patel C, Liu G, van de Velde H, Venkatakrishnan K.

Clin Pharmacol Ther. 2019 Feb;105(2):376-387. doi: 10.1002/cpt.1047. Epub 2018 Mar 23. Review.

29.

Efficacy of protein rich pearl powder on antioxidant status in a randomized placebo-controlled trial.

Chiu HF, Hsiao SC, Lu YY, Han YC, Shen YC, Venkatakrishnan K, Wang CK.

J Food Drug Anal. 2018 Jan;26(1):309-317. doi: 10.1016/j.jfda.2017.05.010. Epub 2017 Jun 13.

30.

Comparative studies on the hypolipidemic, antioxidant and hepatoprotective activities of catechin-enriched green and oolong tea in a double-blind clinical trial.

Venkatakrishnan K, Chiu HF, Cheng JC, Chang YH, Lu YY, Han YC, Shen YC, Tsai KS, Wang CK.

Food Funct. 2018 Feb 21;9(2):1205-1213. doi: 10.1039/c7fo01449j.

PMID:
29384173
31.

Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.

Suri A, Mould DR, Liu Y, Jang G, Venkatakrishnan K.

Clin Pharmacol Ther. 2018 Nov;104(5):989-999. doi: 10.1002/cpt.1037. Epub 2018 Feb 23.

32.

Reverse Translation: The Art of Cyclical Learning.

Kasichayanula S, Venkatakrishnan K.

Clin Pharmacol Ther. 2018 Feb;103(2):152-159. doi: 10.1002/cpt.952.

PMID:
29313963
33.

How Well Are We Applying Quantitative Methods to Reverse Translation to Inform Early Clinical Development?

Heatherington AC, Kasichayanula S, Venkatakrishnan K.

Clin Pharmacol Ther. 2018 Feb;103(2):174-176. doi: 10.1002/cpt.948. Epub 2017 Dec 23.

PMID:
29274086
34.

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.

Faucette S, Wagh S, Trivedi A, Venkatakrishnan K, Gupta N.

Clin Transl Sci. 2018 Mar;11(2):123-146. doi: 10.1111/cts.12527. Epub 2017 Dec 19. Review. No abstract available.

35.

Driving Access to Medicines With a Totality of Evidence Mindset: An Opportunity for Clinical Pharmacology.

Venkatakrishnan K, Cook J.

Clin Pharmacol Ther. 2018 Mar;103(3):373-375. doi: 10.1002/cpt.926. Epub 2017 Nov 28.

PMID:
29193042
36.

Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development.

Teng Z, Gupta N, Hua Z, Liu G, Samnotra V, Venkatakrishnan K, Labotka R.

Clin Transl Sci. 2018 Mar;11(2):218-225. doi: 10.1111/cts.12524. Epub 2017 Nov 23.

37.

Toward Universal SERS Detection of Disease Signaling Bioanalytes Using 3D Self-Assembled Nonplasmonic near-Quantum-Scale Silicon Probe.

Powell JA, Venkatakrishnan K, Tan B.

ACS Appl Mater Interfaces. 2017 Nov 22;9(46):40127-40142. doi: 10.1021/acsami.7b15393. Epub 2017 Nov 8.

PMID:
29083860
38.

Regulatory efficacy of fermented plant extract on the intestinal microflora and lipid profile in mildly hypercholesterolemic individuals.

Chiu HF, Chen YJ, Lu YY, Han YC, Shen YC, Venkatakrishnan K, Wang CK.

J Food Drug Anal. 2017 Oct;25(4):819-827. doi: 10.1016/j.jfda.2016.10.008. Epub 2016 Dec 3.

39.

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.

Gupta N, Zhang S, Pusalkar S, Plesescu M, Chowdhury S, Hanley MJ, Wang B, Xia C, Zhang X, Venkatakrishnan K, Shepard DR.

Invest New Drugs. 2018 Jun;36(3):407-415. doi: 10.1007/s10637-017-0509-1. Epub 2017 Sep 21.

40.

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.

Zhou X, Mould DR, Takubo T, Sheldon-Waniga E, Huebner D, Milton A, Venkatakrishnan K.

Br J Clin Pharmacol. 2018 Jan;84(1):35-51. doi: 10.1111/bcp.13430. Epub 2017 Nov 24.

41.

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.

Zhou X, Pant S, Nemunaitis J, Craig Lockhart A, Falchook G, Bauer TM, Patel M, Sarantopoulos J, Bargfrede M, Muehler A, Rangachari L, Zhang B, Venkatakrishnan K.

Invest New Drugs. 2018 Apr;36(2):248-258. doi: 10.1007/s10637-017-0499-z. Epub 2017 Aug 30.

42.

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.

Zhou X, Nemunaitis J, Pant S, Bauer TM, Patel M, Sarantopoulos J, Craig Lockhart A, Goodman D, Huebner D, Mould DR, Venkatakrishnan K.

Invest New Drugs. 2018 Apr;36(2):240-247. doi: 10.1007/s10637-017-0498-0. Epub 2017 Aug 18.

43.

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.

Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S, Richardson PG, Skacel T, Venkatakrishnan K.

Target Oncol. 2017 Oct;12(5):643-654. doi: 10.1007/s11523-017-0524-3.

44.

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.

Gupta N, Hanley MJ, Venkatakrishnan K, Bessudo A, Rasco DW, Sharma S, O'Neil BH, Wang B, Liu G, Ke A, Patel C, Rowland Yeo K, Xia C, Zhang X, Esseltine DL, Nemunaitis J.

J Clin Pharmacol. 2018 Feb;58(2):180-192. doi: 10.1002/jcph.988. Epub 2017 Aug 11.

45.

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

Hanley MJ, Gupta N, Venkatakrishnan K, Bessudo A, Sharma S, O'Neil BH, Wang B, van de Velde H, Nemunaitis J.

J Clin Pharmacol. 2018 Jan;58(1):114-121. doi: 10.1002/jcph.987. Epub 2017 Aug 7.

PMID:
28783865
46.

Fibroblast-Cytophilic and HeLa-Cytotoxic Dual Function Carbon Nanoribbon Network Platform.

Chowdhury AKMRH, Tan B, Venkatakrishnan K.

ACS Appl Mater Interfaces. 2017 Jun 14;9(23):19662-19676. doi: 10.1021/acsami.7b04819. Epub 2017 May 31.

PMID:
28530092
47.

Bio-functionalizing heterogeneous phase activated titanium by multiphoton ionization energy mechanism to harmonize cell proliferative behavior.

Chinnakkannu Vijayakumar S, Venkatakrishnan K, Tan B.

Mater Sci Eng C Mater Biol Appl. 2017 Jul 1;76:448-456. doi: 10.1016/j.msec.2017.03.111. Epub 2017 Mar 14.

PMID:
28482549
48.

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range.

Hanley MJ, Mould DR, Taylor TJ, Gupta N, Suryanarayan K, Neuwirth R, Esseltine DL, Horton TM, Aplenc R, Alonzo TA, Lu X, Milton A, Venkatakrishnan K.

J Clin Pharmacol. 2017 Sep;57(9):1183-1193. doi: 10.1002/jcph.906. Epub 2017 Apr 18.

49.

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K.

Clin Pharmacokinet. 2017 Nov;56(11):1355-1368. doi: 10.1007/s40262-017-0526-4.

50.

Biofunctionalized 3-D Carbon Nano-Network Platform for Enhanced Fibroblast Cell Adhesion.

Chowdhury AK, Tavangar A, Tan B, Venkatakrishnan K.

Sci Rep. 2017 Mar 13;7:44250. doi: 10.1038/srep44250.

Supplemental Content

Loading ...
Support Center